Aditxt (ADTX) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 11, 2022
Document Information Line Items
Entity Registrant Name	Aditxt, Inc.
Trading Symbol	ADTX
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		4,161,129
Amendment Flag	false
Entity Central Index Key	0001726711
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39336
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-3204328
Entity Address, Address Line One	737 N. Fifth Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Richmond
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23219
City Area Code	(650)
Local Phone Number	870-1200
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash	$ 9,244,876	$ 7,872,061
Accounts receivable, net	662,810	89,844
Prepaid expenses	689,417	460,102
Note receivable	585,372	500,000
Inventory	1,442,426	494,697
TOTAL CURRENT ASSETS	12,624,901	9,416,704
Fixed assets, net	2,248,868	2,267,297
Intangible assets, net	133,750	214,000
ROU asset - long term	3,426,746	4,097,117
Deposits	398,114	379,250
Other assets	347,555	289,539
TOTAL ASSETS	19,179,934	16,663,907
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,711,991	1,575,543
Stock redemption payable - related party	20,000
Notes payable – related party	80,000
Financing on fixed assets – current	246,723	700,433
Deferred rent	191,515	186,058
Lease liability - current	1,122,869	1,145,126
TOTAL CURRENT LIABILITIES	4,373,098	3,607,160
Financing on fixed assets - long term		110,041
Lease liability - long term	2,112,362	2,765,933
TOTAL LIABILITIES	6,485,460	6,483,134
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively
Common stock, $0.001 par value, 100,000,000 shares authorized, 3,733,146 and 890,614 shares issued and 3,731,129 and 888,579 shares outstanding, respectively	3,731	899
Treasury stock, 2,017 and 2,017 shares, respectively	(201,605)	(201,605)
Additional paid-in capital	99,720,486	77,734,288
Accumulated deficit	(86,828,138)	(67,352,809)
TOTAL STOCKHOLDERS’ EQUITY	12,694,474	10,180,773
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 19,179,934	$ 16,663,907

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,733,146	890,614
Common stock, shares outstanding	3,731,129	888,579
Treasury stock	2,017	2,017

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
REVENUE
Sales	$ 323,125		$ 748,119
Cost of goods sold	233,684		596,613
Gross Profit	89,441		151,506
OPERATING EXPENSES
General and administrative expenses, $461,492, $650,325, $1,288,829 and $2,887,657 in stock-based compensation, respectively	3,919,618	4,451,545	12,332,728	14,348,375
Research and development, includes $170,066, $248,989, $473,593 and $248,989 in stock-based compensation, respectively	1,570,540	1,471,544	4,186,842	3,340,247
Sales and marketing $0, $0, $754,699, and $0 in stock-based compensation, respectively	(8,553)	150,056	911,988	252,562
Total operating expenses	5,418,605	6,073,145	17,431,558	17,941,184
NET LOSS FROM OPERATIONS	(5,392,164)	(6,073,145)	(17,280,052)	(17,941,184)
OTHER EXPENSE
Interest expense	(645,381)	(38,198)	(742,701)	(74,587)
Interest income	10,084	42,838	30,131	43,267
Other income			58,960
Loss on extinguishment of debt		(2,500,970)		(2,500,970)
Amortization of debt discount	(1,530,102)	(1,191,254)	(1,533,048)	(1,845,358)
Total other expense	(2,165,399)	(3,687,584)	(2,186,658)	(4,377,648)
Net loss before income taxes	(7,557,563)	(9,760,729)	(19,466,710)	(22,318,832)
Income tax provision
NET LOSS	$ (7,557,563)	$ (9,760,729)	$ (19,466,710)	$ (22,318,832)
Net loss per share - basic and diluted (in Dollars per share)	$ (5.27)	$ (28.08)	$ (18.01)	$ (73.08)
Weighted average number of shares outstanding during the period - basic and diluted (in Shares)	1,433,175	347,610	1,080,661	305,416

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation			$ 2,517,121	$ 3,136,646
Net loss per share - diluted (in Dollars per share)	$ (5.27)	$ (28.08)	$ (18.01)	$ (73.08)
Weighted average number of shares outstanding during the period - diluted (in Shares)	1,433,175	347,610	1,080,661	305,416
General and administrative expenses
Stock-based compensation	$ 461,492	$ 650,325	$ 1,288,829	$ 2,887,657
Research and development
Stock-based compensation	170,066	248,989	473,593	248,989
Sales and marketing
Stock-based compensation	$ 0	$ 0	$ 754,699	$ 0

Condensed Statements of Stockho

Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($)	Preferred B Shares	Preferred Shares	Common Shares	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020			$ 262	$ (201,605)	$ 32,092,003	$ (20,879,178)	$ 11,011,482
Balance (in Shares) at Dec. 31, 2020			259,474
Stock option and warrant compensation					301,462		301,462
Fair value of warrants issued with convertible note payable					1,322,840		1,322,840
Warrant consideration for convertible note offering costs					231,316		231,316
Exercise of warrants			$ 24		3,718,932		3,718,956
Exercise of warrants (in Shares)			23,272
Issuance of shares for services			$ 1		51,239		51,240
Issuance of shares for services (in Shares)			360
Issuance of shares for employee compensation			$ 7		1,112,193		1,112,200
Issuance of shares for employee compensation (in Shares)			6,700
Net loss						(6,379,667)	(6,379,667)
Balance at Mar. 31, 2021			$ 294	(201,605)	38,829,985	(27,258,845)	11,369,829
Balance (in Shares) at Mar. 31, 2021			289,806
Balance at Dec. 31, 2020			$ 262	(201,605)	32,092,003	(20,879,178)	11,011,482
Balance (in Shares) at Dec. 31, 2020			259,474
Net loss							(22,318,832)
Balance at Sep. 30, 2021			$ 490	(201,605)	56,473,723	(43,300,277)	12,972,331
Balance (in Shares) at Sep. 30, 2021			481,862
Balance at Mar. 31, 2021			$ 294	(201,605)	38,829,985	(27,258,845)	11,369,829
Balance (in Shares) at Mar. 31, 2021			289,806
Stock option and warrant compensation					259,070		259,070
Issuance of shares for services			$ 2		181,858		181,860
Issuance of shares for services (in Shares)			1,360
Issuance of shares for employee compensation			$ 3		331,497		331,500
Issuance of shares for employee compensation (in Shares)			2,600
Net loss						(6,178,436)	(6,178,436)
Balance at Jun. 30, 2021			$ 299	(201,605)	39,602,410	(33,437,281)	5,963,823
Balance (in Shares) at Jun. 30, 2021			293,766
Stock option and warrant compensation					219,885		219,885
Issuance of shares for the settlement of debt			$ 97		5,749,825		5,749,922
Issuance of shares for the settlement of debt (in Shares)			96,050
Issuance of restricted stock units for compensation					674,265		674,265
Restricted stock unit compensation			$ 1		(1)
Restricted stock unit compensation (in Shares)			320
Issuance of shares and warrants for offering, net of issuance costs			$ 92		10,119,909		10,120,001
Issuance of shares and warrants for offering, net of issuance costs (in Shares)			91,667
Issuance of shares for services			$ 1		5,163		5,164
Issuance of shares for services (in Shares)			59
Down round					102,267	(102,267)
Net loss						(9,760,729)	(9,760,729)
Balance at Sep. 30, 2021			$ 490	(201,605)	56,473,723	(43,300,277)	12,972,331
Balance (in Shares) at Sep. 30, 2021			481,862
Balance at Dec. 31, 2021			$ 899	(201,605)	77,734,288	(67,352,809)	10,180,773
Balance (in Shares) at Dec. 31, 2021			888,597
Stock option and warrant compensation					219,885		219,885
Issuance of restricted stock units for compensation			$ 6		(6)
Issuance of restricted stock units for compensation (in Shares)			5,744
Restricted stock unit compensation					377,671		377,671
Issuance of shares for services			$ 1		3,718		3,719
Issuance of shares for services (in Shares)			180
Net loss						(6,059,141)	(6,059,141)
Balance at Mar. 31, 2022			$ 906	(201,605)	78,335,556	(73,411,950)	4,722,907
Balance (in Shares) at Mar. 31, 2022			894,521
Balance at Dec. 31, 2021			$ 899	(201,605)	77,734,288	(67,352,809)	10,180,773
Balance (in Shares) at Dec. 31, 2021			888,597
Net loss							(19,466,710)
Balance at Sep. 30, 2022			$ 3,731	(201,605)	99,720,486	(86,828,138)	12,694,474
Balance (in Shares) at Sep. 30, 2022			3,731,129
Balance at Mar. 31, 2022			$ 906	(201,605)	78,335,556	(73,411,950)	4,722,907
Balance (in Shares) at Mar. 31, 2022			894,521
Stock option and warrant compensation					724,584		724,584
Issuance of restricted stock units for compensation			$ 3		(3)
Issuance of restricted stock units for compensation (in Shares)			2,751
Restricted stock unit compensation					309,704		309,704
Exercise of warrants, modification of warrants, and issuance of warrants			$ 180		1,203,589		1,203,769
Exercise of warrants, modification of warrants, and issuance of warrants (in Shares)			179,419
Issuance of shares for services			$ 31		249,969		250,000
Issuance of shares for services (in Shares)			30,685
Net loss						(5,850,006)	(5,850,006)
Balance at Jun. 30, 2022			$ 1,120	(201,605)	80,823,399	(79,261,956)	1,360,958
Balance (in Shares) at Jun. 30, 2022			1,107,376
Stock option and warrant compensation					338,439		338,439
Restricted stock unit compensation			$ 7		293,112		293,119
Restricted stock unit compensation (in Shares)			6,621
Sale of Series B Preferred shares to related party					20,000		20,000
Sale of Series B Preferred shares to related party (in Shares)	1
Redemption of Series B Preferred shares to related party					(20,000)		(20,000)
Redemption of Series B Preferred shares to related party (in Shares)	(1)
Shares issued as inducement on loans, net of issuance costs			$ 48		146,474		146,522
Shares issued as inducement on loans, net of issuance costs (in Shares)			47,779
Warrants issued with loans					878,622		878,622
Anti-dilution reset of warrants					8,619	(8,619)
Issuance of shares for debt issuance costs			$ 11		96,019		96,030
Issuance of shares for debt issuance costs (in Shares)			10,477
Exercise of warrants			$ 1,337		(1,337)
Exercise of warrants (in Shares)			1,336,917
Issuance of shares and warrants for offering, net of issuance costs			$ 1,224		17,231,331		17,232,555
Issuance of shares and warrants for offering, net of issuance costs (in Shares)			1,224,333
Issuance of shares for services modification			$ (14)		14
Issuance of shares for services modification (in Shares)			(14,389)
Issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants					(94,195,000,000)		(94,195,000,000)
Rounding from reverse stock split			$ (2)		(11)		(13)
Rounding from reverse stock split (in Shares)			12,015
Net loss						(7,557,563)	(7,557,563)
Balance at Sep. 30, 2022			$ 3,731	$ (201,605)	$ 99,720,486	$ (86,828,138)	$ 12,694,474
Balance (in Shares) at Sep. 30, 2022			3,731,129

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,466,710)	$ (22,318,832)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	2,517,121	3,136,646
Depreciation expense	296,685	266,385
Amortization of intangible assets	80,250	80,030
Amortization of debt discount	1,533,048	1,845,358
Loss on extinguishment of debt		2,500,970
Changes in operating assets and liabilities:
Accounts receivable	(229,315)	(268,430)
Prepaid expenses	(18,864)	(243,359)
Accounts payable and accrued expenses	1,136,448	1,414,363
Deposits	(572,966)
Inventory	(947,729)
Net cash used in operating activities	(15,672,032)	(13,586,869)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(278,256)	(900,693)
Tenant improvement allowance receivable	(87,934)	(226,738)
Deferred acquisition costs		(152,630)
Notes receivable and accrued interest	(55,454)	(6,542,740)
Net cash used in investing activities	(421,644)	(7,822,801)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable - related party	80,000
Proceeds from note payable	3,138,888	5,000,000
Discount on note payable from offering costs	(411,887)	(526,460)
Repayments of note payable	(3,138,888)	(315,790)
Sale of Series B Preferred shares to related party	20,000
Common stock and warrants issued for cash, net of issuance costs	17,232,555	10,120,001
Exercise of warrants		3,718,956
Exercise of warrants, modification of warrants, and issuance of warrants	1,109,574
Payments on financing on fixed asset	(563,751)	(418,428)
Cash paid on extinguishment of note payable		(1,200,000)
Net cash provided by financing activities	17,466,491	16,378,279
NET INCREASE (DECREASE) IN CASH	1,372,815	(5,031,391)
CASH AT BEGINNING OF PERIOD	7,872,061	10,500,826
CASH AT END OF PERIOD	9,244,876	5,469,435
Supplemental cash flow information:
Cash paid for income taxes
Cash paid for interest expense	740,301	15,789
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of shares for the settlement of notes payable		5,749,922
Lease liability recognized from right of use asset		2,806,427
Original offering discount on convertible note payable		1,000,000
Debt discount from warrants issued with convertible note payable	878,622	1,322,840
Debt discount from warrant consideration for convertible debt offering costs		231,316
Debt discount from shares issued as inducement for convertible note payable	174,522
Liability recognized for financed assets		821,862
Reduction in exercise price of warrants		102,267
Shares issued for debt offering costs	96,030
Redemption of Series B Preferred shares to related party	20,000
Anti-dilution reset of warrants modification	$ 8,619

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Overview Aditxt, Inc. (“Aditxt” or the “Company”), formerly known as Aditx Therapeutics, Inc., was incorporated in the State of Delaware on September 28, 2017, and the Company’s headquarters are located in Richmond, VA. The Company is a biotech innovation company with a mission of prolonging life and enhancing its quality by improving the health of the immune system. The Company is developing biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. The Company’s immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system, and the Company plans to utilize them in its upcoming reprogramming clinical trials to monitor subjects’ immune response before, during and after drug administration. Reverse Stock Split On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company’s common stock. All shares amounts referenced in this report are adjusted to reflect the Reverse Split. Offerings On August 31, 2021, the Company completed a registered direct offering (“August 2021 Offering”). In connection therewith, the Company issued 91,667 shares of common stock, at a purchase price of $120.00 per share, resulting in gross proceeds of approximately $11.0 million. In a concurrent private placement, the Company issued warrants to purchase up to 91,667 shares. The warrants have an exercise price of $126.50 per share and are exercisable for a five-year period commencing six months from the date of issuance. The warrants exercise price was subsequently repriced to $75.00. In addition, the Company issued a warrant to the placement agent to purchase up to 4,584 shares of common stock at an exercise price of $150.00 per share. On October 18, 2021, the Company entered into an underwriting agreement with Revere Securities LLC, relating to the public offering (the “October 2021 Offering”) of 56,667 shares of the Company’s common stock (the “Shares”) by the Company. The Shares were offered, issued, and sold at a price to the public of $75.00 per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13, 2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25 million. The Company utilized a portion of the proceeds, net of underwriting discounts of approximately $3.91 million from the October 2021 Offering to fund certain obligations under the Credit Agreement. (See Note 4) On December 6, 2021, we completed a public offering for net proceeds of $16.0 million (the “December 2021 Offering”). As part of the December 2021 Offering, we issued 164,929 units consisting of shares of the Company’s common stock and warrant to purchase shares of the Company’s common stock and 166,572 prefunded warrants. The warrant issued as part of the units had an exercise price of $57.50 and the prefunded warrants had an exercise price of $0.001. On June 15, 2022, the Company entered an agreement with a holder of certain warrants in the December 2021 Offering. (See Note 10) On September 20, 2022, we completed a public offering for net proceeds of $18.1 million (the “September 2022 Offering”). As part of the September 2022 Offering, we issued 1,224,333 of shares of the Company’s common stock, pre-funded warrants to purchase 2,109,000 shares of common stock, and warrants to purchase 3,333,333 shares of the Company’s common stock. The warrants had an exercise price of $6.00 and the pre-funded warrants had an exercise price of $0.001. Risks and Uncertainties The Company has a limited operating history and is in the very early stages of generating revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations. On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raising efforts and additional development of our technologies may be negatively affected.

Going Concern Analysis

Going Concern Analysis	9 Months Ended
	Sep. 30, 2022
Going Concern Analysis [Abstract]
GOING CONCERN ANALYSIS	NOTE 2 – GOING CONCERN ANALYSIS Management Plans The Company was incorporated on September 28, 2017 and has not generated significant revenues to date. During the nine months ended September 30, 2022, the Company had a net loss of $19,466,710 and negative cash flow from operating activities of $15,672,032. As of September 30, 2022, the Company’s cash balance was $9,244,876. The Company has $67.3 million of remaining availability, subject to regulatory requirements, to raise future funds pursuant to an effective shelf registration statement filed with the SEC on Form S-3 declared effective on July 13, 2021. However, SEC regulations limit the amount of funds we can raise during any 12-month period pursuant to our effective shelf registration statement on Form S-3. We are currently subject to General Instruction I.B.6 to Form S-3, or the Baby Shelf Rule, and the amount of funds we can raise through primary public offerings of securities in any 12-month period using our shelf registration statement on Form S-3 is limited to one-third of the aggregate market value of the voting and non-voting common stock held by non-affiliates. We are currently limited by the Baby Shelf Rule as of the filing of this Quarterly Report, until such time as our public float exceeds $75 million. In addition to the shelf registration, the Company has the ability to raise capital from equity or debt through private placements or public offerings pursuant to a registration statement on Form S-1. We may also secure loans from related parties. However, factors such as stock price, volatility, trading volume, market conditions, demand and regulatory requirements may adversely affect the Company’s ability to raise capital in an efficient manner. Because of these factors, the Company believes that this creates substantial doubt with the Company’s ability to continue as a going concern. The condensed financial statements included in this report do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein. The Company’s ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating expenses. In addition, the Company is consistently focused on raising capital, strategic acquisitions and alliances, and other initiatives to strengthen the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying condensed financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2022 and September 30, 2021. Although management believes that the disclosures in these unaudited condensed financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in condensed financial statements that have been prepared in accordance U.S. GAAP have been omitted pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. The interim results for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or for any future interim periods. Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed financial statements include the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair value of stock options and warrants. Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates. Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. Cash and Cash Equivalents Cash and cash equivalents include short-term, liquid investments. Inventory Inventory consists of laboratory materials and supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable. Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related assets. Intangible Assets Intangible assets are stated at cost less accumulated amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are stated at the amount management expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management. As of September 30, 2022 and December 31, 2021, there was an allowance for doubtful accounts of $49,233 and zero, respectively. Revenue Recognition In accordance with ASC 606 (Revenue From Contracts with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 1) Identify the contract with a customer 2) Identify the performance obligations in the contract 3) Determine the transaction price 4) Allocate the transaction price to performance obligations in the contract 5) Recognize revenue when or as the Company satisfies a performance obligation Revenues reported from services relating to the AditxtScore™ are recognized when the AditxtScore TM The Company recognizes revenue in the following manner for the following types of customers: Client Payers: Client payers include physicians or other entities for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for client payers based on historical collection experience and the period of time the receivable has been outstanding. Cash Pay: Customers are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the ability of the patients to pay. Insurance: Reimbursements from healthcare insurers are based on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of the Company’s contractual arrangements. Leases Under Topic 842 (Leases), operating lease expense is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space, and lab equipment. Leases with an initial term of twelve months or less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right of use (“ROU”) assets. Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. Patents The Company incurs fees from patent licenses, which are expensed as incurred. During the nine months ended September 30, 2022 and September 30, 2021, the Company incurred patent licensing fees for the patents of $256,589 and $76,245, respectively. Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. During the nine months ended September 30, 2022 and September 30, 2021, the Company incurred research and development costs of $4,186,842 and $3,340,247, respectively. Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of September 30, 2022, 44,712 stock options, 10,556 unvested restricted stock units, and 5,522,224 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of September 30, 2021, 42,860 stock options, 28,576 unvested restricted stock units and 205,280 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our condensed financial statements.

Note Receivable

Note Receivable	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
NOTE RECEIVABLE	NOTE 4 – NOTE RECEIVABLE Cellvera Global Note Receivable On August 25, 2021, the Company entered into a letter of intent (“the LOI”) to acquire AiPharma Global Holdings LLC, a Delaware limited liability company, which subsequently changed its name to Cellvera Global Holdings LLC (“Cellvera Global”) which is commercializing COVID-19 antiviral oral therapy. Key terms of the proposed transaction as stated in the Letter of Intent included: the completion of a proposed $6.5 million secured loan from the Company to Cellvera Global by August 31, 2021, as well as the issuance of such number of shares of the Company’s common stock that yields 50% of the number of the Company’s outstanding shares post-closing of the transaction. The acquisition is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed to be issued in the transaction. The Company and Cellvera Global agreed to an exclusivity period until September 30, 2021 (the “Exclusivity Period”), with a view to settling the definitive agreement. On September 30, 2021, the parties entered into a letter agreement pursuant to which they agreed to extend the Exclusivity Period until October 4, 2021. On December 28, 2021, we entered into a Share Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we (i) will acquire 9.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of $250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing. Additionally, we may elect to raise additional capital due to market conditions or strategic considerations. In connection with the contemplated acquisition with Cellvera Global, the Company entered into a secured credit agreement dated August 27, 2021 (the “Credit Agreement”) with Cellvera Global and certain affiliated entities (collectively, the “Borrower”), pursuant to which the Company made a secured loan to Cellvera Global in the principal amount of $6.5 million (the “Loan”). The Loan was funded on August 31, 2021, following the closing of the Company’s August 2021 Offering. The Loan bears interest at a rate of 8% per annum and matured on November 30, 2021. The Loan is secured by certain accounts receivable and other assets of Cellvera Global and certain of its affiliates. The Credit Agreement also contains certain covenants that prohibit Cellvera Global from incurring additional indebtedness, incurring liens or making any dispositions of its property. On October 18, 2021, the Company entered into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the “Credit Agreement Amendment”), pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by $8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment. The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the Company from the exercise of existing warrants or any other capital raises, including the October Offering. As of December 31, 2021, an additional $8.0 million was advanced under the Credit Agreement for a total of $14.5 million. The Credit Agreement was amended on multiple occasions, for which the final amendment was signed on December 31, 2021, extending the Loan’s maturity date to January 31, 2022. The Company determined that Cellvera Global may not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of $14.5 million as of December 31, 2021. Forbearance Agreement: On January 31, 2022, the Company’s $14.5 million loan to Cellvera Global became fully due and payable under the Credit Agreement. On February 14, 2022, the Company entered into a Forbearance Agreement and Seventh Amendment to Credit Agreement (the “Forbearance Agreement”) with Cellvera Global. Pursuant to the Forbearance Agreement, the Company agreed to forbear from exercising its rights and remedies against Cellvera Global and certain affiliated guarantor parties until the earlier of (i) June 30, 2022 or (ii) the date of occurrence of any event of default under the Forbearance Agreement (the “Forbearance Period”). Given that the parties continue to conduct due diligence in connection with the Share Exchange Agreement, the Company and Cellvera Global also agreed that should the initial closing occur under the Share Exchange Agreement, the existing event of default will be waived. Under the Forbearance Agreement, the Company and Cellvera Global also agreed to certain amendments to the Credit Agreement, including, but not limited to: (i) the delivery by the Borrower of certain financial statements and forecasts, and (ii) certain regularly scheduled payments to be made by Cellvera Global to the Company during the Forbearance Period. As of the date of filing of this Quarterly Report, the regularly scheduled payments under the Forbearance Agreement have not been made, and the note receivable remains fully impaired. On April 4, 2022, the Company and Cellvera Global entered into a Forbearance Agreement and Eighth Amendment to the Credit Agreement (the “April Forbearance Agreement”) pursuant to which among other things (i) the Company agreed to extend the forbearance period until the earlier of March 31, 2023 or the date of occurrence of any event of default under the April Forbearance Agreement, (ii) Cellvera Global shall be permitted to factor certain receivables, and (iii) certain conforming changes were made relating to the Revenue Sharing Agreement (as defined below). In connection with the Forbearance Agreement, the Company entered into a series of security agreements with Cellvera Global (the “Security Agreements”) and certain affiliated entities pursuant to which Cellvera Global enhanced the Company’s security interest in connection with the Credit Agreement. In addition, and as a condition to entering into the April Forbearance Agreement, the Company required that Cellvera Global enter into a Revenue Sharing Agreement (the “Revenue Sharing Agreement”), pursuant to which, among other things, Cellvera Global agreed to pay the Company a certain portion of its revenues up to the aggregate amount of $30 million. As of the date of filing of this Quarterly Report, the Company has not received any payments from Cellvera Global pursuant to the Revenue Sharing Agreement. Concurrently with the execution of the April Forbearance Agreement and the Revenue Sharing Agreement, the Company and AiPharma Group, Ltd. entered into an Amendment to the Share Exchange Agreement (the “Share Exchange Amendment”) which amended the Share Exchange Agreement to, among other things: (i) modify the financial statements required to be delivered by AiPharma Group, Ltd. at the initial closing to include the unaudited financial statements for the three months ended March 31, 2022 and 2021, (ii) permit the Company to amend its Certificate of Incorporation without the consent of AiPharma Group, Ltd. in order to effect a reverse stock split of the Company’s common stock, if necessary, in order to maintain its listing on the Nasdaq Capital Market, and (iii) make certain other conforming changes related to the March Forbearance Agreement and Revenue Sharing Agreement. Target Company Note Receivable On December 10, 2021, the Company entered into a secured credit agreement dated December 10, 2021 (the “Target Company Credit Agreement”) and signed on December 10, 2021 with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $500,000 (the “Target Company Loan”) and agreed to make additional secured loans, as requested by the Target Company and approved by the Company, in an amount not to exceed $4.5 million. The Target Company Loan bears interest at a rate of 8% per annum and mature on December 8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security interest in all of the Target Company’s assets as security for the Target Company Loan. As of September 30, 2022, the outstanding principal of the Target Company Loan is $500,000 and the accrued interest on the Loan is $32,438. Future Receipt Agreements Overpayment On September 30, 2022, the Company paid off the Future Receipts Agreement and the Agreement (as defined in Note 8). This resulted in overpayments of $56,572 and $28,800, respectively. These amounts are reflected as notes receivable and are deemed collectible.

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS The Company’s fixed assets include the following on September 30, 2022: Cost Basis Accumulated Net Computers $ 370,029 $ (166,635 ) $ 203,394 Lab Equipment 2,497,273 (509,267 ) 1,988,006 Office Furniture 56,656 (6,784 ) 49,872 Other Fixed Assets 8,605 (1,009 ) 7,596 Total Fixed Assets $ 2,932,563 $ (683,695 ) $ 2,248,868 The Company’s fixed assets include the following on December 31, 2021: Cost Basis Accumulated Net Computers $ 312,489 $ (75,053 ) $ 237,436 Lab Equipment 2,240,252 (306,688 ) 1,933,564 Office Furniture 90,757 (4,857 ) 85,900 Other Fixed Assets 10,809 (412 ) 10,397 Total Fixed Assets $ 2,654,307 $ (387,010 ) $ 2,267,297 Depreciation expense was $99,980 and $99,857, for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $296,684 and $266,385, for the nine months ended September 30, 2022 and 2021, respectively. None of the Company’s fixed assets serve as collateral against any loans as of September 30, 2022 and December 31, 2021, other than those subject to the financed asset liability.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 6 – INTANGIBLE ASSETS The Company’s intangible assets include the following on September 30, 2022: Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (187,250 ) $ 133,750 Total Intangible Assets $ 321,000 $ (187,250 ) $ 133,750 The Company’s intangible assets include the following on December 31, 2021: Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (107,000 ) $ 214,000 Total Intangible Assets $ 321,000 $ (107,000 ) $ 214,000 Amortization expense was $26,750 and $26,970 for the three months ended September 30, 2022 and 2021, respectively. Amortization expense was $80,250 and $80,030 for the nine months ended September 30, 2022 and 2021, respectively. None of the Company’s intangible assets serve as collateral against any loans as of September 30, 2022 and December 31, 2021.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS On January 28, 2022, the Company granted 9,600 restricted stock units to an officer of the Company pursuant to the Company’s 2021 Equity Incentive Plan. The Company recognized $126,613 in stock-based compensation for the issuance of these vested and unvested restricted stock units during the period ended September 30, 2022. (Note 10) On July 19, 2022, the Company entered into a Subscription and Investment Representation Agreement with its Chief Executive Officer (the “Purchaser”), pursuant to which the Company agreed to issue and sell one (1) share of the Company’s Series B Preferred Stock (the “Preferred Stock”), par value $0.001 per share, to the Purchaser for $20,000 in cash. On July 19, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides that the share of Preferred Stock will have 250,000,000 votes and will vote together with the outstanding shares of the Company’s common stock as a single class exclusively with respect to any proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. The Preferred Stock will be voted, without action by the holder, on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled to receive dividends of any kind. The outstanding share of Preferred Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split. Upon such redemption, the holder of the Preferred Stock will receive consideration of $20,000 in cash. On September 13, 2022, the share was redeemed. On July 21, 2022, the Chief Executive Officer loaned $80,000 to the Company. The loan was evidenced by an unsecured promissory note (the “Promissory Note”). Pursuant to the terms of the Promissory Note, it will accrue interest at a rate of four and three-quarters percent (4.75%) per annum, the Prime rate on the date of signing, and is due on the earlier of January 22, 2023, or an event of default.

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2022
Note Payable [Abstract]
NOTE PAYABLE	NOTE 8 – NOTE PAYABLE On May 27, 2022, the Company entered into an agreement for the purchase and sale of future receipts (the “Future Receipts Agreement”) with a commercial funding source pursuant to which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $792,000 (the “Future Receipts Purchased Amount” for gross proceeds to the Company of $550,000, less origination fees of $16,500 and professional service fees of $13,500. Pursuant to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company’s present and future accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be repaid by the Company in 28 weekly installments of approximately $28,000 with the final payment due on December 7, 2022. As of September 30, 2022, the principal balance and accrued interest was paid off in full. On August 31, 2022, the Company entered into an Agreement for the Purchase and Sale of Future Receipts (the “Agreement”) with a commercial funding source pursuant to which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount $288,000 (the “Purchased Amount”) for gross proceeds to the Company of $200,000, less origination fees of $20,000. Pursuant to the Agreement, the Company granted the funder a security interest in all of the Company’s present and future accounts receivable in an amount not to exceed the Purchased Amount. The Purchased Amount shall be repaid by the Company in 20 weekly installments of approximately $14,400 with the final payment due on January 18, 2023. In connection with the Agreement, the Company also issued a warrant to purchase 26,667 shares of the Company’s common stock. As of September 30, 2022, the principal balance and accrued interest was paid off in full. Convertible Note Financing: On August 4, 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors to purchase $1,277,778 in principal amount 10% Senior Secured Promissory Notes (the “August 2022 Notes”), resulting in gross proceeds to the Company of $1,150,000, exclusive of placement agent commission and fees and other offering expenses. In connection therewith, the Company issued, 25,556 shares of common stock as commitment fees and warrants (the “August 2022 Warrants”) to purchase up to 108,517 shares of the Company’s common stock. On August 11, 2022, the Company entered into a SPA with certain accredited investors to purchase $555,556 in principal amount of August 2022 Notes, resulting in gross proceeds to the Company of $500,000. In connection therewith, the Company issued 11,112 shares of common stock as commitment fees and August 2022 Warrants to purchase up to 47,182 shares of the Company’s common stock. The August 2022 Notes have a maturity date of twelve (12) months from the date of issuance and are convertible at the option of the Investor at any time prior to maturity in shares of Common Stock (the “Conversion Shares”) at an initial conversion price of $11.78 per share, subject to adjustments. The August 2022 Warrants are exercisable for a period of five (5) years from the period commencing on the commencement date (as defined in the August 2022 Warrant) and ending on 5:00 p.m. eastern standard time on the date that is five (5) years after the date of issuance, at an initial exercise price of $11.78, subject to adjustment provided therein (including cashless exercise). On August 25, 2022, the Company entered into a First Amendment and Waiver with the holders of the August 2022 Warrants, pursuant to which the exercise price of the August 2022 Warrants was reduced to $7.50 per share and the August 2022 Warrants were modified such that they are not exercisable unless and until the Company obtains stockholder approval of the issuance of any shares of common stock upon exercise of the August 2022 Warrants. On September 16, 2022, the exercise price of the August 2022 Warrants was further adjusted to $6.00 per share. Convertible Note Financing Follow On: On September 12, 2022, the Company entered into a SPA with a certain accredited investor to purchase $555,555 in principal amount of August 2022 Notes, resulting in gross proceeds to the Company of $500,000. In connection therewith, the Company issued 11,112 shares of common stock as commitment fees and warrants (the “August 2022 Follow On Warrants”) to purchase up to 74,074 shares of the Company’s common stock. The August 2022 Follow On Warrants are exercisable for a period of five (5) years from the period commencing on the commencement date (as defined in the August 2022 Follow On Warrant) and ending on 5:00 p.m. eastern standard time on the date that is five (5) years after the date of issuance, at an initial exercise price of $7.50, subject to adjustments. On September 16, 2022, the exercise price of the August 2022 Follow On Warrants was adjusted to $6.00 per share. As of September 30, 2022, the principal balance of $2,388,889, prepayment penalty of $238,889 and accrued interest of $119,444 relating to the August 2022 Notes was paid off in full.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
LEASES	NOTE 9 – LEASES Our lease agreements generally do not provide an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments. We used the incremental borrowing rate on September 30, 2022 and December 31, 2021 for all leases that commenced prior to that date. In determining this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay on a collateralized basis, with similar payment terms as the lease and in a similar economic environment. Lease Costs Nine Months Nine Months Components of total lease costs: Operating lease expense $ 988,381 $ 515,956 Total lease costs $ 988,381 $ 515,956 Lease Positions as of September 30, 2022 and December 31, 2021 ROU lease assets and lease liabilities for our operating leases are recorded on the balance sheet as follows: September 30, December 31, Assets Right of use asset – long term $ 3,426,746 $ 4,097,117 Total right of use asset $ 3,426,746 $ 4,097,117 Liabilities Operating lease liabilities – short term $ 1,122,869 $ 1,145,126 Operating lease liabilities – long term 2,112,362 2,765,933 Total lease liability $ 3,235,231 $ 3,911,059 Lease Terms and Discount Rate Weighted average remaining lease term (in years) – operating leases 1.80 Weighted average discount rate – operating leases 8.00 %

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 10 – STOCKHOLDERS’ EQUITY Common Stock On May 24, 2021, the Company increased the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 27,000,000 to 100,000,000 (the “Authorized Shares Increase”) by filing a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In accordance with the General Corporation Law of the State of Delaware, the Authorized Shares Increase and the Certificate of Amendment were approved by the stockholders of the Company at the Company’s Annual Meeting of Stockholders on May 19, 2021. On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “Reverse Split”). The Company’s stock began trading at the Reverse Split price effective on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company’s common stock. During the nine months ended September 30, 2022, the Company issued 16,476 shares of common stock and recognized expense of $253,719 in stock-based compensation for consulting services. The Company also granted 11,644 Restricted Stock Units and, 15,153 Restricted Stock Units vested which resulted in the issuance of shares. As a result, the Company recognized expense of $993,462 in stock-based compensation. The stock-based compensation for shares issued or RSU’s granted during the period were valued based on the fair market value on the date of grant. The Company issued 58,257 shares in relation to the issuance of notes (See Note 8). The Company issued 1,224,333 shares of common stock as part of the September 2022 Offering. The Company also issued 1,337,000 shares of common stock as a result of the exercise of prefunded warrants from the September 2022 Offering. During the nine months ended September 30, 2021, the Company issued 1,779 shares of common stock and recognized expense of $238,264 in stock-based compensation for consulting services. The Company also issued 23,272 shares of common stock upon the exercise of warrants and received $3,718,956 in cash proceeds. The Company granted 9,300 shares of restricted common stock for employee compensation and recognized expense of $1,443,700 in stock-based compensation. The Company also granted 28,908 Restricted Stock Units, of which 320 vested and resulted in the issuance of shares, as a result, the Company recognized expense of $674,265 in stock-based compensation. The Company issued 96,050 shares of common stock for the conversion of a convertible note. The Company issued 91,667 shares of common stock as part of the August 2021 Offering. The stock-based compensation for shares issued or RSU’s granted during the period, were valued based on the fair market value on the date of grant. Preferred Stock The Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share. There were no shares of preferred stock outstanding as of September 30, 2022 and December 31, 2021, respectively. Issuance of Series B Preferred Stock: On July 19, 2022, the Company entered into a Subscription and Investment Representation Agreement with its Chief Executive Officer (the “Purchaser”), pursuant to which the Company agreed to issue and sell one (1) share of the Company’s Series B Preferred Stock (the “Preferred Stock”), par value $0.001 per share, to the Purchaser for $20,000 in cash. On July 19, 2022, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides that the share of Preferred Stock will have 250,000,000 votes and will vote together with the outstanding shares of the Company’s common stock as a single class exclusively with respect to any proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. The Preferred Stock will be voted, without action by the holder, on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled to receive dividends of any kind. The outstanding share of Preferred Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split. Upon such redemption, the holder of the Preferred Stock will receive consideration of $20,000 in cash. On September 13, 2022, the share was redeemed. Stock-Based Compensation In October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of equity awards to directors, employees, and consultants. The Company is authorized to issue up to 2,500,000 shares of our common stock pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after adoption, unless terminated earlier by the Board of Directors. All shares of our common stock pursuant to awards under the 2017 Plan have been awarded. On February 24, 2021, our Board of Directors adopted the Aditx Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides for grants of nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units, and other stock-based awards (collectively, the “Awards”). Eligible recipients of Awards include employees, directors or independent contractors of the Company or any affiliate of the Company. The Compensation Committee of the Board of Directors (the “Committee”) will administer the 2021 Plan. A total of 60,000 shares of common stock, par value $0.001 per share, of the Company may be issued pursuant to Awards granted under the 2021 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a stock option will be no less than one hundred percent (100%) of the Fair Market Value (as defined in the 2021 Plan) of a share of Common Stock on the date of grant. The 2021 Plan was submitted and approved by the Company’s stockholders at the 2021 annual meeting of stockholders, held on May 19, 2021. During the nine months ended September 30, 2022 and 2021, the Company granted no new options. The following is an analysis of the stock option grant activity under the Plan: Vested and Nonvested Stock Options Number Weighted Weighted Outstanding December 31, 2021 44,710 $ 170.00 6.74 Granted - - - Exercised - - - Expired or forfeited - - - Outstanding September 30, 2022 44,710 $ 170.00 5.99 Nonvested Stock Options Number Weighted- Nonvested on December 31, 2021 9,063 $ 108.50 Granted - - Vested (6,088 ) 110.23 Forfeited - - Nonvested on September 30, 2022 2,975 $ 105.71 The Company recognized stock-based compensation expense related to options granted and vesting expense of $660,191 during the nine months ended September 30, 2022, of which $472,156 is included in general and administrative expenses and $188,035 is included in research and development expenses in the accompanying statements of operations. The remaining value to be expensed is $310,887 with a weighted average vesting term of 0.88 years as of September 30, 2022. The Company recognized stock-based compensation expense related to options issued and vesting of $616,781 during the nine months ended September 30, 2021, which $556,817 is included in general and administrative expenses and $59,964 is included in research and development expenses in the accompanying statements of operations. Warrants During the nine months ended September 30, 2022 the Company issued 6,423,456 warrants. During the nine months ended September 30, 2021, the Company issued 113,750 warrants. For the nine months ended September 30, 2022, the fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model as follows: Exercise price $ 7.50-20.00 Expected dividend yield 0 % Risk free interest rate 2.55%-3.47 % Expected life in years 5.00-5.50 Expected volatility 147%-165 % For the nine months ended September 30, 2021, the fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model as follows: Exercise price $ 200.00 Expected dividend yield 0 % Risk free interest rate 0.17%-0.42 % Expected life in years 3.00-5.00 Expected volatility 154%-159 % The risk-free interest rate assumption for warrants granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term of warrants. The Company determined the expected volatility assumption for warrants granted using the historical volatility of comparable public companies’ common stock. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future warrant grants, until such time that the Company’s common stock has enough market history to use historical volatility. The dividend yield assumption for warrants granted is based on the Company’s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future. The Company recognizes warrant forfeitures as they occur as there is insufficient historical data to accurately determine future forfeitures rates. A summary of warrant issuances are as follows: Vested and Nonvested Warrants Number Weighted Weighted Outstanding December 31, 2021 601,400 $ 83.50 4.38 Granted 6,497,530 4.71 4.90 Exercised (1,516,419 ) 0.89 - Expired or forfeited (60,312 ) 38.33 - Rounding for Reverse Split 25 - - Outstanding September 30, 2022 5,522,224 $ 11.93 4.80 Nonvested Warrants Number Weighted- Nonvested on December 31, 2021 92,567 $ 75.50 Granted 6,497,530 4.71 Vested (6,016,340 ) 5.00 Forfeited (55,000 ) 20.00 Nonvested on September 30, 2022 518,757 $ 11.45 The Company recognized stock-based compensation expense related to warrants granted and vesting expense of $609,748 during the nine months ended September 30, 2022, of which $105,049 is included in general and administrative and $504,699 is included in sales and marketing in the accompanying Statements of Operations. The Company recognized stock-based compensation expense related to warrants granted and vesting expense of $163,637 during the nine months ended September 30, 2021, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to be expensed is zero as of September 30, 2022. The weighted average vesting term is zero as of September 30, 2022. On June 15, 2022, the Company entered an agreement with a holder of certain of the Series C Warrants (the “Holder”). Pursuant to the agreement, the Holder has agreed to exercise in cash 179,419 of its Series C Warrants at a reduced exercise price of $7.50 per Share (reduced from $57.50 per share), for gross proceeds to the Company of approximately $1.35 million. As an inducement to such exercise, the Company has agreed to reduce the exercise price of the Holder’s remaining Series C Warrants to purchase up to 49,153 Shares from $57.50 to $12.395 per share, which will be non-exercisable for a period of six months following the closing date. The modification of this exercise price resulted in an increase of $344,158 to the fair value of the Series C Warrants. This modification was an inducement on the transaction and as such was recoded to equity resulting in no net change to additional paid in capital. In addition, the Company issued to the Holder a new warrant to purchase up to 407,991 shares of the Company’s common stock at an exercise price of $12.395 per share, which will be non-exercisable for a period of six months following issuance date and have a term of five and one-half years. This inducement resulted in a total increase of $3,759,044 to the fair value of the warrants. Restricted Stock Units A summary of Restricted Stock Units (“RSUs”) issuances are as follows: Nonvested RSUs Number Weighted Nonvested December 31, 2021 15,565 $ 96.00 Granted 11,644 22.74 Vested (15,153 ) 68.20 Forfeited (1,500 ) 77.42 Nonvested September 30, 2022 10,556 $ 57.87 The Company recognized stock-based compensation expense related to RSUs granted and vesting expense of $993,462 and $674,265 during the nine months ended September 30, 2022 and September 30, 2021, respectively, of which, $707,904 is included in general and administrative and $285,558 is included in research and development in the accompanying Statements of Operations. The remaining value to be expensed is $551,684 with a weighted average vesting term of 0.57 years as of September 30, 2022. During the nine months ended September 30, 2022, the Company granted a total of 11,644 RSUs. As of September 30, 2022, 15,513 RSUs vested and the Company issued 15,153 shares of common stock for the 15,153vested RSUs.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Taxes [Abstract]
INCOME TAXES	NOTE 11 – INCOME TAXES The Company has incurred losses since inception. During the nine months ended September 30, 2022, the Company did not provide any provision for income taxes as the Company incurred losses during such period. The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. In assessing the need for a valuation allowance, the Company has considered both positive and negative evidence related to the likelihood of realization of deferred tax assets using a “more likely than not” standard. In making such assessment, more weight was given to evidence that could be objectively verified, including recent cumulative losses. Based on the Company’s review of this evidence, the Company has recorded a full valuation allowance for its net deferred tax assets as of September 30, 2022. As of September 30, 2022, the Company did not have any amounts recorded pertaining to uncertain tax positions.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS Redemption of Series B Preferred Stock On October 7, 2022, the Company paid $20,000 in consideration for the one share of Preferred Stock which was redeemed on September 13, 2022. Repayment of Promissory Note On October 7, 2022, the Company fully repaid the $80,000 Promissory Note and $812 of accrued interest to its Chief Executive Officer. The Chief Executive Officer and the Company entered the Promissory Note on July 21, 2022.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, the accompanying condensed financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2022 and September 30, 2021. Although management believes that the disclosures in these unaudited condensed financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in condensed financial statements that have been prepared in accordance U.S. GAAP have been omitted pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. The interim results for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2022 or for any future interim periods.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed financial statements include the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair value of stock options and warrants.
Fair Value Measurements and Fair Value of Financial Instruments	Fair Value Measurements and Fair Value of Financial Instruments The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include short-term, liquid investments.
Inventory	Inventory Inventory consists of laboratory materials and supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related assets.
Intangible Assets	Intangible Assets Intangible assets are stated at cost less accumulated amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are stated at the amount management expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management. As of September 30, 2022 and December 31, 2021, there was an allowance for doubtful accounts of $49,233 and zero, respectively.
Revenue Recognition	Revenue Recognition In accordance with ASC 606 (Revenue From Contracts with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: 1) Identify the contract with a customer 2) Identify the performance obligations in the contract 3) Determine the transaction price 4) Allocate the transaction price to performance obligations in the contract 5) Recognize revenue when or as the Company satisfies a performance obligation Revenues reported from services relating to the AditxtScore™ are recognized when the AditxtScore TM The Company recognizes revenue in the following manner for the following types of customers: Client Payers: Client payers include physicians or other entities for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for client payers based on historical collection experience and the period of time the receivable has been outstanding. Cash Pay: Customers are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the ability of the patients to pay. Insurance: Reimbursements from healthcare insurers are based on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of the Company’s contractual arrangements.
Leases	Leases Under Topic 842 (Leases), operating lease expense is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space, and lab equipment. Leases with an initial term of twelve months or less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right of use (“ROU”) assets.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services.
Patents	Patents The Company incurs fees from patent licenses, which are expensed as incurred. During the nine months ended September 30, 2022 and September 30, 2021, the Company incurred patent licensing fees for the patents of $256,589 and $76,245, respectively.
Research and Development	Research and Development We incur research and development costs during the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs qualify for capitalization under applicable guidance. During the nine months ended September 30, 2022 and September 30, 2021, the Company incurred research and development costs of $4,186,842 and $3,340,247, respectively.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As of September 30, 2022, 44,712 stock options, 10,556 unvested restricted stock units, and 5,522,224 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of September 30, 2021, 42,860 stock options, 28,576 unvested restricted stock units and 205,280 warrants were excluded from dilutive earnings per share as their effects were anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our condensed financial statements.

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of fixed assets	Cost Basis Accumulated Net Computers $ 370,029 $ (166,635 ) $ 203,394 Lab Equipment 2,497,273 (509,267 ) 1,988,006 Office Furniture 56,656 (6,784 ) 49,872 Other Fixed Assets 8,605 (1,009 ) 7,596 Total Fixed Assets $ 2,932,563 $ (683,695 ) $ 2,248,868 Cost Basis Accumulated Net Computers $ 312,489 $ (75,053 ) $ 237,436 Lab Equipment 2,240,252 (306,688 ) 1,933,564 Office Furniture 90,757 (4,857 ) 85,900 Other Fixed Assets 10,809 (412 ) 10,397 Total Fixed Assets $ 2,654,307 $ (387,010 ) $ 2,267,297

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (187,250 ) $ 133,750 Total Intangible Assets $ 321,000 $ (187,250 ) $ 133,750 Cost Basis Accumulated Net Proprietary Technology $ 321,000 $ (107,000 ) $ 214,000 Total Intangible Assets $ 321,000 $ (107,000 ) $ 214,000

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases (Tables) [Line Items]
Schedule of lease costs	Nine Months Nine Months Components of total lease costs: Operating lease expense $ 988,381 $ 515,956 Total lease costs $ 988,381 $ 515,956
Schedule of ROU lease assets and lease liabilities for our operating leases	September 30, December 31, Assets Right of use asset – long term $ 3,426,746 $ 4,097,117 Total right of use asset $ 3,426,746 $ 4,097,117 Liabilities Operating lease liabilities – short term $ 1,122,869 $ 1,145,126 Operating lease liabilities – long term 2,112,362 2,765,933 Total lease liability $ 3,235,231 $ 3,911,059
Schedule of lease terms and discount rate	Weighted average remaining lease term (in years) – operating leases 1.80 Weighted average discount rate – operating leases 8.00 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of analysis of the stock option grant activity under the plan	Vested and Nonvested Stock Options Number Weighted Weighted Outstanding December 31, 2021 44,710 $ 170.00 6.74 Granted - - - Exercised - - - Expired or forfeited - - - Outstanding September 30, 2022 44,710 $ 170.00 5.99 Vested and Nonvested Warrants Number Weighted Weighted Outstanding December 31, 2021 601,400 $ 83.50 4.38 Granted 6,497,530 4.71 4.90 Exercised (1,516,419 ) 0.89 - Expired or forfeited (60,312 ) 38.33 - Rounding for Reverse Split 25 - - Outstanding September 30, 2022 5,522,224 $ 11.93 4.80 Nonvested RSUs Number Weighted Nonvested December 31, 2021 15,565 $ 96.00 Granted 11,644 22.74 Vested (15,153 ) 68.20 Forfeited (1,500 ) 77.42 Nonvested September 30, 2022 10,556 $ 57.87
Schedule of fair value of each warrant granted	Nonvested Stock Options Number Weighted- Nonvested on December 31, 2021 9,063 $ 108.50 Granted - - Vested (6,088 ) 110.23 Forfeited - - Nonvested on September 30, 2022 2,975 $ 105.71 Nonvested Warrants Number Weighted- Nonvested on December 31, 2021 92,567 $ 75.50 Granted 6,497,530 4.71 Vested (6,016,340 ) 5.00 Forfeited (55,000 ) 20.00 Nonvested on September 30, 2022 518,757 $ 11.45
Schedule of fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model	Exercise price $ 7.50-20.00 Expected dividend yield 0 % Risk free interest rate 2.55%-3.47 % Expected life in years 5.00-5.50 Expected volatility 147%-165 % Exercise price $ 200.00 Expected dividend yield 0 % Risk free interest rate 0.17%-0.42 % Expected life in years 3.00-5.00 Expected volatility 154%-159 %

Organization and Nature of Bu_2

Organization and Nature of Business (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Oct. 20, 2021	Oct. 18, 2021	Aug. 31, 2021	Sep. 20, 2022	Dec. 06, 2021
Organization and Nature of Business (Details) [Line Items]
Gross proceeds	$ 4,250		$ 11,000
Company issued		56,667	91,667	1,224,333	164,929
Purchase price per share			$ 120
Issued warrants to purchase of shares			91,667
Debt instrument term, description			The warrants have an exercise price of $126.50 per share and are exercisable for a five-year period commencing six months from the date of issuance.
Warrants exercise price			$ 75	$ 6	$ 57.5
Purchase of common stock			4,584	3,333,333
Exercise price per share		$ 75	$ 150
Net of underwriting discounts	$ 3,910
Net proceeds				$ 18,100	$ 16,000
Prefunded warrants shares				2,109,000	166,572
Pre funded warrants price per share				$ 0.001
Warrant [Member]
Organization and Nature of Business (Details) [Line Items]
Warrants exercise price			$ 126.5
Pre funded warrants price per share					$ 0.001

Going Concern Analysis (Details

Going Concern Analysis (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Going Concern Analysis [Abstract]
Net loss cash flow from operating activities	$ 19,466,710
Net Income (Loss) Available to Common Stockholders, Basic	(15,672,032)
Cash	9,244,876
Future funds	67,300,000
Exceeds amounts	$ 75,000,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 49,233		$ 0
Licensing fees	256,589	$ 76,245
Research and development expense	$ 4,186,842	$ 3,340,247
Stock options issued	44,712	42,860
Restricted stock units	10,556
Dilutive earning shares	5,522,224	28,576
Warrants		205,280

Note Receivable (Details)

Note Receivable (Details) - USD ($)			1 Months Ended			9 Months Ended	12 Months Ended
	Apr. 04, 2022	Dec. 10, 2021	Dec. 28, 2021	Oct. 18, 2021	Aug. 25, 2021	Sep. 30, 2022	Dec. 31, 2021	Jan. 31, 2022	Nov. 30, 2021	Aug. 27, 2021
Note Receivable (Details) [Line Items]
Completion of a proposed					$ 6,500,000
Common stock yields percentage					50%
Share exchange agreement description			On December 28, 2021, we entered into a Share Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we (i) will acquire 9.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of $250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.
Principal amount										$ 6,500,000
Interest rate per annum									8%
Credit agreement amendment, description				On October 18, 2021, the Company entered into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the “Credit Agreement Amendment”), pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by $8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment. The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the Company from the exercise of existing warrants or any other capital raises, including the October Offering.
Advanced credit agreement							$ 8,000,000
Credit agreement							14,500,000
Note receivable amount							$ 14,500,000
Loan								$ 14,500,000
Aggregate amount	$ 30,000,000
Credit agreement description		the Company entered into a secured credit agreement dated December 10, 2021 (the “Target Company Credit Agreement”) and signed on December 10, 2021 with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $500,000 (the “Target Company Loan”) and agreed to make additional secured loans, as requested by the Target Company and approved by the Company, in an amount not to exceed $4.5 million. The Target Company Loan bears interest at a rate of 8% per annum and mature on December 8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security interest in all of the Target Company’s assets as security for the Target Company Loan.
Outstanding Principal loan						$ 500,000
Accured interest loan						32,438
Future Receipts Agreement [Member]
Note Receivable (Details) [Line Items]
Over payments of company						56,572
Agreement [Member]
Note Receivable (Details) [Line Items]
Over payments of company						$ 28,800

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 99,980	$ 99,857	$ 296,684	$ 266,385

Fixed Assets (Details) - Schedu

Fixed Assets (Details) - Schedule of fixed assets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost Basis	$ 2,932,563	$ 2,654,307
Accumulated Depreciation	(683,695)	(387,010)
Net	2,248,868	2,267,297
Computers [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	370,029	312,489
Accumulated Depreciation	(166,635)	(75,053)
Net	203,394	237,436
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	2,497,273	2,240,252
Accumulated Depreciation	(509,267)	(306,688)
Net	1,988,006	1,933,564
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	56,656	90,757
Accumulated Depreciation	(6,784)	(4,857)
Net	49,872	85,900
Other Fixed Assets [Member]
Property, Plant and Equipment [Line Items]
Cost Basis	8,605	10,809
Accumulated Depreciation	(1,009)	(412)
Net	$ 7,596	$ 10,397

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 26,750	$ 26,970	$ 80,250	$ 80,030

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets, Cost Basis	$ 321,000	$ 321,000
Total Intangible Assets, Accumulated Amortization	(187,250)	(107,000)
Total Intangible Assets, Net	133,750	214,000
Proprietary Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets, Cost Basis	321,000	321,000
Total Intangible Assets, Accumulated Amortization	(187,250)	(107,000)
Total Intangible Assets, Net	$ 133,750	$ 214,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		1 Months Ended		9 Months Ended
	Jul. 19, 2022	Jul. 19, 2022	Jan. 28, 2022	Sep. 30, 2022	Jul. 21, 2022
Related Party Transactions (Details) [Line Items]
Restricted stock of shares (in Shares)			9,600
Preferred stock value per share (in Dollars per share)	$ 0.001	$ 0.001
Cash	$ 20,000
Preferred stock votes (in Shares)	250,000,000	250,000,000
Consideration cash				$ 20,000
Company loan amount				80,000
Accrued interest rate percentage					4.75%
RSUs [Member]
Related Party Transactions (Details) [Line Items]
Restricted stock issued				$ 126,613

Note Payable (Details)

Note Payable (Details) - USD ($)					1 Months Ended
	Sep. 12, 2022	Aug. 11, 2022	Aug. 04, 2022	Aug. 01, 2022	Sep. 30, 2022	Aug. 31, 2022	Aug. 31, 2022	May 27, 2022	Sep. 16, 2022
Note Payable (Details) [Line Items]
Aggregate amount							$ 288,000	$ 792,000
Gross proceeds	$ 500,000	$ 500,000					200,000	550,000
Origination fee								16,500
Professional service fees							20,000	13,500
Installments amount						$ 14,400	$ 14,400	$ 28,000
Purchase shares (in Shares)	74,074	47,182	108,517				26,667
Purchase price	$ 555,555	$ 555,556	$ 1,277,778
Principal percentage			10%
Commission fees			$ 1,150,000
Common stock shares (in Shares)	11,112	11,112	25,556
Conversion price per share (in Dollars per share)				$ 11.78
Warrants exercisable				5 years
Standard time				5 years
Exercise price per share (in Dollars per share)				$ 11.78
Warrants reduced per share (in Dollars per share)				$ 7.5
Warrants adjusted per share (in Dollars per share)									$ 6
Principal balance					$ 2,388,889
Prepayment					238,889
Accrued interest					$ 119,444
Warrant [Member]
Note Payable (Details) [Line Items]
Warrants exercisable						5 years
Standard time						5 years
Exercise price per share (in Dollars per share)						$ 7.5

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease costs - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Components of total lease costs:
Operating lease expense	$ 988,381	$ 515,956
Total lease costs	$ 988,381	$ 515,956

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Assets
Right of use asset – long term	$ 3,426,746	$ 4,097,117
Total right of use asset	3,426,746	4,097,117
Liabilities
Operating lease liabilities – short term	1,122,869	1,145,126
Operating lease liabilities – long term	2,112,362	2,765,933
Total lease liability	$ 3,235,231	$ 3,911,059

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease terms and discount rate	Sep. 30, 2022
Schedule Of Lease Terms And Discount Rate Abstract
Weighted average remaining lease term (in years) – operating leases	1 year 9 months 18 days
Weighted average discount rate – operating leases	8%

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)		1 Months Ended				3 Months Ended						9 Months Ended
	Jul. 19, 2022	Jul. 19, 2022	Jun. 15, 2022	Feb. 24, 2021	Oct. 31, 2017	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	May 24, 2021
Stockholders’ Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)						$ 0.001			$ 163,637			$ 0.001	$ 163,637	$ 0.001	$ 0.001
Common stock, shares authorized (in Shares)						100,000,000						100,000,000		100,000,000
Company issued shares (in Shares)						15,513						15,513
Stock base compensation for consulting services												$ 253,719	$ 238,264
Preferred stock, shares authorized (in Shares)						3,000,000						3,000,000		3,000,000
Issue of common stock (in Shares)									23,272				23,272
Exercise of warrants and received													$ 3,718,956
Stock based compenastion												2,017	1,443,700
Stock based compensation recognized expense												$ 674,265
Shares of common stock (in Shares)												96,050
Shares of common stock offering (in Shares)												91,667
Preferred stock, par value (in Dollars per share)						$ 0.001						$ 0.001		$ 0.001
Purchase in cash		$ 20,000
Preferred stock votes (in Shares)	250,000,000	250,000,000
Preferred stock receive consideration												$ 20,000
Granted stock options (in Shares)				60,000
Fair market value				100%
Vesting expense												993,462	674,265
General and administrative expenses						$ 3,919,618			$ 4,451,545			12,332,728	14,348,375
Research and development expenses						$ 1,570,540			1,471,544			4,186,842	3,340,247
Share based payment remaining expenses												$ 310,887
Weighted average vesting term												10 months 17 days
Options granted and vesting expense									$ 616,781				616,781
General and administrative expenses													556,817
Research and development expense												$ 285,558	$ 59,964
Granted warrants (in Shares)									205,280				205,280
General and administrative												105,049
Sales and marketing												$ 504,699
Pursuant agreement, description			Pursuant to the agreement, the Holder has agreed to exercise in cash 179,419 of its Series C Warrants at a reduced exercise price of $7.50 per Share (reduced from $57.50 per share), for gross proceeds to the Company of approximately $1.35 million. As an inducement to such exercise, the Company has agreed to reduce the exercise price of the Holder’s remaining Series C Warrants to purchase up to 49,153 Shares from $57.50 to $12.395 per share, which will be non-exercisable for a period of six months following the closing date. The modification of this exercise price resulted in an increase of $344,158 to the fair value of the Series C Warrants. This modification was an inducement on the transaction and as such was recoded to equity resulting in no net change to additional paid in capital. In addition, the Company issued to the Holder a new warrant to purchase up to 407,991 shares of the Company’s common stock at an exercise price of $12.395 per share, which will be non-exercisable for a period of six months following issuance date and have a term of five and one-half years.
Weighted average vesting term												6 months 25 days
Remaining value												$ 551,684
Total granted (in Shares)												11,644
Common stock, shares issued (in Shares)						15,153						15,153
2017 Equity Incentive Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Recognized expense (in Shares)					2,500,000
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Company issued shares (in Shares)						16,476						16,476
Recognized expense (in Shares)							30,685	180	59	1,360	360
Shares vested (in Shares)												15
Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized (in Shares)						58,257						58,257
Stock Based Compensation [Member]
Stockholders’ Equity (Details) [Line Items]
Granted shares (in Shares)												9,300
Vesting expense												$ 660,191
Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Restricted stock units (in Shares)												28,908
Granted warrants (in Shares)						6,423,456			113,750			6,423,456	113,750
Warrants issued and vesting expense												$ 609,748
Fair value of warrants			$ 3,759,044
Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, shares authorized (in Shares)															27,000,000
Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, shares authorized (in Shares)															100,000,000
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)				$ 0.001
Company issued shares (in Shares)						1,779						1,779
Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized (in Shares)						3,000,000						3,000,000
Series B Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Series B Preferred Stock [Member] | Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Recognized expense (in Shares)
Restricted Stock Units (RSUs) [Member]
Stockholders’ Equity (Details) [Line Items]
Number of shares, granted (in Shares)												11,644
Number of shares, vested (in Shares)												15,153
General and administrative expenses												$ 707,904
Restricted Stock Units (RSUs) [Member] | Stock Based Compensation [Member]
Stockholders’ Equity (Details) [Line Items]
General and administrative expenses												472,156
Research and development expenses												$ 188,035

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan - $ / shares	9 Months Ended
	Sep. 30, 2022
Vested and Nonvested Stock Options [Member]
Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]
Number, Outstanding beginning balance	44,710
Weighted Average Exercise Price, Outstanding beginning balance	$ 170
Weighted Average Remaining Life, Outstanding beginning balance	6 years 8 months 26 days
Number, Granted
Weighted Average Exercise Price, Granted
Weighted Average Remaining Life, Granted
Number, Exercised
Weighted Average Exercise Price, Exercised
Weighted Average Remaining Life, Exercised
Number, Expired or forfeited
Weighted Average Exercise Price, Expired or forfeited
Weighted Average Remaining Life, Expired or forfeited
Number, Outstanding ending balance	44,710
Weighted Average Exercise Price, Outstanding ending balance	$ 170
Weighted Average Remaining Life, Outstanding ending balance	5 years 11 months 26 days
Vested and Nonvested Warrants [Member]
Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]
Number, Outstanding beginning balance	601,400
Weighted Average Exercise Price, Outstanding beginning balance	$ 83.5
Weighted Average Remaining Life, Outstanding beginning balance	4 years 4 months 17 days
Number, Granted	6,497,530
Weighted Average Exercise Price, Granted	$ 4.71
Weighted Average Remaining Life, Granted	4 years 10 months 24 days
Number, Exercised	(1,516,419)
Weighted Average Exercise Price, Exercised	$ 0.89
Weighted Average Remaining Life, Exercised
Number, Expired or forfeited	(60,312)
Weighted Average Exercise Price, Expired or forfeited	$ 38.33
Weighted Average Remaining Life, Expired or forfeited
Number, Rounding for Reverse Split	25
Weighted Average Exercise Price, Rounding for Reverse Split
Weighted Average Remaining Life, Rounding for Reverse Split
Number, Outstanding ending balance	5,522,224
Weighted Average Exercise Price, Outstanding ending balance	$ 11.93
Weighted Average Remaining Life, Outstanding ending balance	4 years 9 months 18 days
Nonvested RSUs [Member]
Stockholders’ Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]
Number, Outstanding beginning balance	15,565
Weighted Average Exercise Price, Outstanding beginning balance	$ 96
Number, Granted	11,644
Weighted Average Exercise Price, Granted	$ 22.74
Number, Vested	(15,153)
Weighted Average Price, Vested	$ 68.2
Number, Forfeited	(1,500)
Weighted Average Price, Forfeited	$ 77.42
Number, Outstanding ending balance	10,556
Weighted Average Exercise Price, Outstanding ending balance	$ 57.87

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Nonvested Stock Options [Member]
Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted [Line Items]
Number, Nonvested at beginning balance | shares	9,063
Weighted- Average Exercise Price, Nonvested at beginning balance | $ / shares	$ 108.5
Number, Granted | shares
Weighted- Average Exercise Price, Granted | $ / shares
Number, Vested | shares	(6,088)
Weighted- Average Exercise Price, Vested | $ / shares	$ 110.23
Number, Forfeited | shares
Weighted- Average Exercise Price, Forfeited | $ / shares
Number, Nonvested at ending balance | shares	2,975
Weighted- Average Exercise Price, Nonvested at ending balance | $ / shares	$ 105.71
Nonvested Warrants [Member]
Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted [Line Items]
Number, Nonvested at beginning balance | shares	92,567
Weighted- Average Exercise Price, Nonvested at beginning balance | $ / shares	$ 75.5
Number, Granted | shares	6,497,530
Weighted- Average Exercise Price, Granted | $ / shares	$ 4.71
Number, Vested | shares	(6,016,340)
Weighted- Average Exercise Price, Vested | $ / shares	$ 5
Number, Forfeited | shares	(55,000)
Weighted- Average Exercise Price, Forfeited | $ / shares	$ 20
Number, Nonvested at ending balance | shares	518,757
Weighted- Average Exercise Price, Nonvested at ending balance | $ / shares	$ 11.45

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model [Line Items]
Exercise price (in Dollars per share)		$ 200
Expected dividend yield	0%	0%
Minimum [Member]
Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model [Line Items]
Exercise price (in Dollars per share)	$ 7.5
Risk free interest rate	2.55%	0.17%
Expected life in years	5 years	3 years
Expected volatility	147%	154%
Maximum [Member]
Stockholders’ Equity (Details) - Schedule of fair value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model [Line Items]
Exercise price (in Dollars per share)	$ 20
Risk free interest rate	3.47%	0.42%
Expected life in years	5 years 6 months	5 years
Expected volatility	165%	159%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Oct. 07, 2022 USD ($)
Subsequent Events (Details) [Line Items]
Consideration paid	$ 20,000
Promissory note	80,000
Accrued interest	$ 812